Journal article · 2026

A Dual SIRT6/Classical HDAC Inhibitor with Integrated Antiproliferative, Antimigratory, and Pharmacokinetic Advantages Against Pancreatic Cancer

Shiying Zhu, En yu Liang, Bicong Cong, Qiao Li, Cui Yunxia, Lirong Zhang, Leisheng Xu, Yan Zheng, Mingzhu Zhao, Kui Cheng, Jian Zhang

Journal of Medicinal Chemistry · Published 12 November 2026 · DOI 10.1021/acs.jmedchem.6c02028

View at the publisherCite this paper

In brief

“A Dual SIRT6/Classical HDAC Inhibitor with Integrated Antiproliferative, Antimigratory, and Pharmacokinetic Advantages Against Pancreatic Cancer” is a 2026 journal article by Shiying Zhu and 10 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 0 citations as of 18 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
References
45
Authors
11

Abstract

Pancreatic cancer (PC) is highly malignant, with a poor prognosis and high metastatic potential. Given the synergy between sirtuin 6 (SIRT6) and classical histone deacetylase (HDAC) in regulating epithelial−mesenchymal transition (EMT), dual-target inhibitors may offer improved antimetastatic therapy. The lead compound 11e suffers from poor metabolic stability, weak antiproliferative activity, and insufficient antimigratory capacity. Through… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhu, S., Liang, E. Y., Cong, B., Li, Q., Yunxia, C., Zhang, L., Xu, L., Zheng, Y., Zhao, M., Cheng, K., & Zhang, J. (2026). A Dual SIRT6/Classical HDAC Inhibitor with Integrated Antiproliferative, Antimigratory, and Pharmacokinetic Advantages Against Pancreatic Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02028

MLA 9

Zhu, Shiying, et al. “A Dual SIRT6/Classical HDAC Inhibitor with Integrated Antiproliferative, Antimigratory, and Pharmacokinetic Advantages Against Pancreatic Cancer.” Journal of Medicinal Chemistry, 2026. https://doi.org/10.1021/acs.jmedchem.6c02028.

Chicago

Zhu, Shiying, En yu Liang, Bicong Cong, Qiao Li, Cui Yunxia, Lirong Zhang, Leisheng Xu, et al. 2026. “A Dual SIRT6/Classical HDAC Inhibitor with Integrated Antiproliferative, Antimigratory, and Pharmacokinetic Advantages Against Pancreatic Cancer.” Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02028.

Harvard

Zhu, S. et al. (2026) ‘A Dual SIRT6/Classical HDAC Inhibitor with Integrated Antiproliferative, Antimigratory, and Pharmacokinetic Advantages Against Pancreatic Cancer’, Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.6c02028.

IEEE

S. Zhu et al., “A Dual SIRT6/Classical HDAC Inhibitor with Integrated Antiproliferative, Antimigratory, and Pharmacokinetic Advantages Against Pancreatic Cancer,” Journal of Medicinal Chemistry, 2026, doi: 10.1021/acs.jmedchem.6c02028.

BibTeX

@article{zhu2026dual,
  title     = {{A Dual SIRT6/Classical HDAC Inhibitor with Integrated Antiproliferative, Antimigratory, and Pharmacokinetic Advantages Against Pancreatic Cancer}},
  author    = {Zhu, Shiying and Liang, En yu and Cong, Bicong and Li, Qiao and Yunxia, Cui and Zhang, Lirong and Xu, Leisheng and Zheng, Yan and Zhao, Mingzhu and Cheng, Kui and Zhang, Jian},
  journal   = {Journal of Medicinal Chemistry},
  year      = {2026},
  doi       = {10.1021/acs.jmedchem.6c02028},
  url       = {https://doi.org/10.1021/acs.jmedchem.6c02028}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research

  • pancreatic cancer
  • SIRT6
  • histone deacetylase inhibitors
  • dual inhibitors
  • epithelial-mesenchymal transition
  • cell migration
  • antiproliferative activity
  • liver metastasis

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Zhu, S., Liang, E. Y., Cong, B., Li, Q., Yunxia, C., Zhang, L., Xu, L., Zheng, Y., Zhao, M., Cheng, K., & Zhang, J. (2026). A Dual SIRT6/Classical HDAC Inhibitor with Integrated Antiproliferative, Antimigratory, and Pharmacokinetic Advantages Against Pancreatic Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02028

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Shiying Zhu, En yu Liang, Bicong Cong, Qiao Li, Cui Yunxia, Lirong Zhang, Leisheng Xu, Yan Zheng, Mingzhu Zhao, Kui Cheng, Jian Zhang.

What is the DOI of this paper?

10.1021/acs.jmedchem.6c02028, permanently at https://doi.org/10.1021/acs.jmedchem.6c02028. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.